These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29599065)

  • 1. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
    Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
    J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.
    Kim MS; Lim DY; Kim JE; Chen H; Lubet RA; Dong Z; Bode AM
    Mol Carcinog; 2015 Dec; 54(12):1596-604. PubMed ID: 25328014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).
    Vedell PT; Lu Y; Grubbs CJ; Yin Y; Jiang H; Bland KI; Muccio DD; Cvetkovic D; You M; Lubet R
    Mol Pharmacol; 2013 Mar; 83(3):698-708. PubMed ID: 23292798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.
    Williams AP; Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
    J Surg Res; 2018 Aug; 228():54-62. PubMed ID: 29907230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
    Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
    Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
    Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
    Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
    Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
    ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
    Wagner CE; Jurutka PW
    Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
    Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C
    Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
    Garner EF; Stafman LL; Williams AP; Aye JM; Goolsby C; Atigadda VR; Moore BP; Nan L; Stewart JE; Hjelmeland AB; Friedman GK; Beierle EA
    J Neurooncol; 2018 Nov; 140(2):209-224. PubMed ID: 30132166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
    Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
    J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.
    Waters AM; Stewart JE; Atigadda VR; Mroczek-Musulman E; Muccio DD; Grubbs CJ; Beierle EA
    Mol Cancer Ther; 2015 Jul; 14(7):1559-69. PubMed ID: 25944918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation.
    Vosper J; Masuccio A; Kullmann M; Ploner C; Geley S; Hengst L
    Oncotarget; 2015 Feb; 6(5):2889-902. PubMed ID: 25605247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway.
    Foster JS; Fernando RI; Ishida N; Nakayama KI; Wimalasena J
    J Biol Chem; 2003 Oct; 278(42):41355-66. PubMed ID: 12904306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
    Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
    Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.